At a glance
- Originator Novartis
- Class Antihypertensives; Phosphonic acids; Tetrazoles
- Mechanism of Action Endopeptidase inhibitors; Endothelin-converting enzyme 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cerebral vasospasm; Heart failure; Hypertension
Most Recent Events
- 10 Feb 2006 No development reported - Preclinical for Cerebral vasospasm in USA (unspecified route)
- 10 Feb 2006 No development reported - Preclinical for Heart failure in France (unspecified route)
- 04 Apr 2002 Preclinical trials in Heart failure in France (unspecified route)